Summary
In stable patients with a history of atherosclerosis, the investigational protease-activated receptor (PAR)-1 antagonist vorapaxar was effective at reducing further atherothrombotic events. This article presents data from the Thrombin Receptor Antagonist in Secondary Prevention-TIMI 50 Trial [TRA 2P; NCT00526474] which showed that vorapaxar significantly reduced the risk of deaths from cardiovascular disease, myocardial infarction, or stroke compared with placebo.
- Thrombotic Disorders Clinical Trials
- © 2012 MD Conference Express®
Tools
Evaluation of a Novel Antiplatelet Agent for Secondary Prevention in Patients with Atherosclerotic Disease: Results from the TRA 2P-TIMI 50 Trial
Permalink:
Table of contents
Cited By...
- No citing articles found.